C-XD6CPraetego
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-XD6C
C-XD6CC-XD6C0-100 chain-logic scale · 15 dimensions · scored on public evidence
Panelists: Pepper Landson, CPC: Praetego, Inc. https://www.linkedin.com/in/praetegopepper/ Veronique Bouchet, MBA: PrecisionLife https://www.linkedin.com/in/veronique-bouchet-172132/ Lidia Sobków, PhD: AbbVie https://www.linkedin.com/in/lidiasobkow/ Host: Elaine Hamm, PhD: Tulane Medicine https://www.linkedin.com/in/elaine-hamm-phd/ For more information regarding Bio on the Bayou 2024 and the upcoming Bio on the Bayou on October 30th & 29th, 2025, please visit https://bioonthebayou.com Video edited by Ian McLachlan (https://www.linkedin.com/in/ian-mclachlan-702a64247/) Filmed by Bernel Davis (https://www.linkedin.com/in/bernel-davis/) #academicmedicine #biotech #highereducation #neworleans #bioonthebayou
Introduction of the Emerging Company Showcase Moderators: Dennis Purcell, Founder of Aisling Capital LLC Pepper Landson, Co-Founder & CEO, Praetego Phil Newman, CEO & Founder Longevity Technology October 13, 2022
A Metabesity 2021 Emerging Company Showcase presentation on Praetego by Pepper Landson, Co-Founder and CEO. Praetego is developing first-in-class advanced glycation end-product inhibitors able to deter AGE formation at the initiation of pathology. Praetego’s candidates are designed to slow or prevent diseases driven by oxidative stress, essentially the chronic diseases of aging. This includes the highly burdensome diseases of neurodegeneration & Alzheimer's, diabetic microvascular disease, and cardiovascular disease. Praetego’s management team are veteran product developers. Praetego’s scientific leadership has spent 3 decades studying AGE inhibitors. We have preclinical proof against variety of indications and clinical efficacy data from an early candidate. Praetego has active programs in serious diabetic complications and Alzheimer’s Disease. We are 12 months away from filing an IND and initiating clinical trials.
Listen to the full episode here: https://bit.ly/2HA0ixu Subscribe to the Supportedly podcast here: https://apple.co/2DiroEx Supportedly's website: https://supportedly.com Follow us on social media: Facebook: https://www.facebook.com/supportedly/ Instagram: @Supportedly Twitter: @Supportedly
Build, Grow, and Scale: How a … - The Diamond Podcast for Financial Advisors - Apple Podcasts Search Home New Top Charts Search June 20, 2024 52 min Build, Grow, and Scale: How a Young Bank Brokerage Team is Achieving Their Goals in Independence The Diamond Podcast for Financial Advisors Play With Dustin Cali and Daniel Ventura – Founding Partners, Praetego Private Wealth Overview While the built-in referral mechanism of a bank brokerage firm can help grow a client base, over time, the firm’s “guardrails” naturally limit those who have their sights set on creating something bigger and better.
The Diamond Podcast for Financial Advisors: Former Bank Brokers on How to Build, Grow and Scale Wealth Management is part of the Informa Connect Division of Informa PLC INFORMA PLC | ABOUT US | INVESTOR RELATIONS | TALENT This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726. Podcasts & Videos CE Webinars Research Newsletters Subscribe Subscribe News Related Topics RIA IBD Wirehouse RPA Insights & Analysis Regulat
Improving Your Leadership Skil… ‑ The Supportedly Podcast ‑ Apple Podcasts Rechercher Accueil Nouveautés Classements Rechercher 28 mai 2019 15 min Improving Your Leadership Skills as a Science-Based Entrepreneur with Praetego Co-Founder & CEO, Pepper Landson The Supportedly Podcast Lire Pepper Landson is the CEO and Co-Founder of Praetego, a business that develops drug candidates for protecting patients with diabetes, patients who receive critical care, and patients who are undergoing surgery. She has held the position of Co-Founder and Principal for Cheval Noir, Vice President of Clinical
034 Launching Larger Than Life Biotech Companies into the Entrepreneurial Ecosystem with Joan Siefert Rose | Supportedly Skip to content Learn Online Training Explore Content Search By Topic Ask Questions & Answers Ask a Question Find Support Directory Find Your Local Chapter Find Your SBC Log In Sign Up Learn Online Training Explore Content Search By Topic Ask Questions & Answers Ask a Question Find Support Directory Find Your Local Chapter Find Your SBC Log In Sign Up Podcasts 034 Launching Larger Than Life Biotech Companies into the Entrepreneurial Ecosystem with Joan Siefert Rose S … p Season 1 with Our Favorite Entrepreneurial Advice Listen → 039 NC IDEA: Grant Application Best Practices & Mistakes to Avoid with John Austin Listen → Browse All Podcasts Receive Insights You Won't Delete, From Our Hearts To Your Brains Footer Email Signup Form Email Address * We won't share your email, but we can't wait to share our newsletter with you. * I agree to Supportedly's terms & conditions and privacy policy .* reCAPTCHA If you are human, leav
ONWARD NC! » LaunchBio event Skip to content Search Events Search Submit Programs Larger than Life Science Investor Connect Investor Connect Plus LaunchBio Networking NextGen VC Forum Invest in Cures Webinars NextGen VC Podcast Biotech Career Workshop Founders circle Events Event Archive News About Donate Sponsors Contact Programs Larger than Life Science Investor Connect Investor Connect Plus LaunchBio Networking NextGen VC Forum Invest in Cures Webinars NextGen VC Podcast Biotech Career Workshop Founders circle Events Event Archive News About Donate Sponsors Contact Building a strong ne
Curiosity-Driven Diabetes Innovation with Praetego | Next Phase Newsletter Life Science Nation Next Phase Newsletter Search Next Phase Newsletter Home Hot Mandates Previous Issues Podcast Subscribe Curiosity-Driven Diabetes Innovation with Praetego 14 Jul By Rory McCann, Marketing Manager & Conference Producer, LSN Pepper Landson has been driven by curiosity and molded by a problem-solving worldview for many years, from childhood to starting her career in HIV/AIDS research. The drive she’s developed has led her into early success with Praetego , a preclinical biotech using novel small … xt Innovator’s Pitch Challenge? Join RESI Partnering Week , September 13-17 and apply for a chance to pitch to a panel of active investors who are relevant for your product and stage of development. Sign up by August 6 to save! Apply for RESI Sept.13-15 Apply for RESI AI Sept.16-17 Apply for RESI Longevity Sept.16-17 Share this: Share on X (Opens in new window) X Share on LinkedIn (Opens in new window) LinkedIn Share on Facebook (Opens in new window) Facebook Email a link to … offices throughout Asia, New York, and San Diego. The firm has closed its fifth fund in 2017 and is currently raising a sixth fund, which the firm is targeting to be the largest fund to date. The firm continues to actively seek investment opportunities across a […] LSN Twitter Tweets by LSciNation Follow Next Phase Newsletter on WordPress.com Contact us +1 (617) 600-0668 [email protected] Archives Archives Select Month June 2026 (14) May 2026 (26)
Praetego, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Praetego, Inc. Startups | Holding Company | 2017 | North Carolina, United States | < 10 | www.praetego.com Startups | Holding Company | 2017 | North Carolina, United States | < 10 | www.praetego.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Nervous System Diseases Endocrinology and Metabolic Disease Eye Diseases Small molecule drug Disease domain … eurodegenerative diseases related to aging, is pleased to announce a $0.3M STTR award from the National Eye Institute. The Phase 1 award advances Praetego's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy. Praetego's proprietary small molecules ("Amadorins") are already demonstrating neuroprotection in the central and peripheral nervous systems in multiple models of neurodegenerative diseases associated with aging. It is now established that … ped as a novel oral candidate for DR, a desired alternative to injectables. The award allows Praetego to establish the merits of PTG-630 ahead of a clinical program. Praetego's NEI grant expands PTG-630 to a third indication and builds upon promising findings in both Alzheimer's disease and diabetic peripheral neuropathy. It complements active awards from the National Institute of Aging and the National Institute of Diabetes and Digestive and Kidney Diseases. This award initi … eurodegenerative diseases related to aging, is pleased to announce a $2.5M STTR award from the National Institute of Aging (NIA). The Phase 2 award advances Praetego's lead candidate, PTG-630, against Alzheimer's disease (AD). Praetego's proprietary small molecule candidates ("Amadorins") recently demonstrated neuroprotection in the central and peripheral nervous systems in preclinical models of both AD and diabetic peripheral neuropathy (DPN). Protection against mild cogniti … cognitive impairment and biomarker evidence of neuronal benefit were found. The award allows Praetego to accelerate development of PTG-630 towards preventing the progression of Alzheimer's Disease (AD). Praetego intends to file an IND in 2023. Praetego's grant follows promising findings obtained during a supplemental award from the NIA targeted a
Praetego Private Wealth | Sanctuary Wealth For Breakaways For Independents Our People Leadership Team Board of Managers Partner Firms Culture & Benefits Culture Benefits Careers Media & Insights Login Contact For Breakaways For Independents Our People Leadership Team Board of Managers Partner Firms Culture & Benefits Culture Benefits Careers Media & Insights Login Contact Praetego Private Wealth In 2022, Dustin Cali and Daniel Ventura launched their independent firm in Trinity, Florida, after a decade of working together in the Private Client Group at J.P. Morgan. Visit Web
Raja G. Khalifah - Chief Scientific Officer at Praetego | The Org Platform Enrich Pricing Log in Sign up Praetego Raja G. Khalifah Unverified Raja G. Khalifah Chief Scientific Officer Contact Raja G. Khalifah, PhD, is a broadly trained chemist and biochemist who transitioned from academia to directing research at three startups (BioStratum, NephroGenex, Praetego) founded on discoveries from his research. He leverages his extensive experience in medicinal chemistry and drug design, pharmacokinetics and drug metabolism, and preclinical and clinical studies. Dr. Khalifah is the primary co-inven
First Flight Venture Center — Pepper Landson About Programs Hangar6 Membership Graduates Resources for Startups Signature Events Sponsorships AgBio + AgTech Events Member Portal Contact Donate Back Our Story Why First Flight? Impact Reports Meet Our Team Board of Directors Meet Our Navigators Meet Our Resident Companies Back Our Programs 2024/25 FAST SBIR Funding Program BARDA DRIVe: Health Security Innovation Funding Business Incubator Captain's Circle Itineraries: Science Talk LiftOff: Strategic Non-dilutive Funding Navigators: Advisors and Business Mentoring Pilots Lounge Propeller Pr … Test Flight: Pitch Practice WheelsUP Accelerator Wingspan Back 2025 High Flyer Award Luncheon 2025 BBQ, Brews & Band 2025 March Madness Open House 2024 High Flyer Award Luncheon 2024 Boil, Brews & Band 2024 March Madness Open House Back Meet Our Sponsors Become a Sponsor About Our Story Why First Flight? Impact Reports Meet Our Team Board of Directors Meet Our Navigators Meet Our Resident Companies Programs Our Programs 2024/25 FAST SBIR Funding Program BARDA DRIVe: Health S … r6 Membership Graduates Resources for Startups Signature Events 2025 High Flyer Award Luncheon 2025 BBQ, Brews & Band 2025 March Madness Open House 2024 High Flyer Award Luncheon 2024 Boil, Brews & Band 2024 March Madness Open House Sponsorships Meet Our Sponsors Become a Sponsor AgBio + AgTech NC PREMIER RESEARCH INCUBATOR Events Member Portal Contact Donate Pepper Landson CEO & Co-Founder of Praetego Pepper Landson has been a driving force in novel therapeutics for crit
Praetego Inc Awarded $2.5M by the NIH National Institute of Aging to Advance Novel Drug Candidate Against Alzheimer's Disease - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deal … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Policy Praetego Inc Awarded $2.5M by the NIH National Institute of Aging to Advance Novel Drug Candidate Against Alzheimer’s Disease October 4, 2022 | 2 min read Twitter LinkedIn Facebook Email Print Praetego Inc is pleased to announce a $2.5M STTR award from the National Institute of Aging. DURHAM, N … eurodegenerative diseases related to aging, is pleased to announce a $2.5M STTR award from the National Institute of Aging (NIA) . The Phase 2 award advances Praetego's lead candidate, PTG-630, against Alzheimer's disease (AD). Praetego's proprietary small molecule candidates ("Amadorins") recently demonstrated neuroprotection in the central and peripheral nervous systems in preclinical models of both AD and diabetic peripheral neuropathy (DPN). Protection against mild cognit … cognitive impairment and biomarker evidence of neuronal benefit were found. The award allows Praetego to accelerate development of PTG-630 towards preventing the progression of Alzheimer's Disease (AD). Praetego intends to file an IND in 2023. Praetego's grant follows promising findings obtained during a supplemental award from the NIA targeted at novel AD therapeutics. It complements sequential awards from the National Institute of Diabetes and Digestive and Kidney Diseases … ief Scientific Officer, Dr. Raja G. Khalifah, the Principal Investigator of the award. Says Praetego's Chief Medical Officer, Dr. Rachel Schindler, "This is an extremely innovative approach to inhibiting the pathogenesis of AD. The pathophysiology caused by AGEs is important in the generation of key pathological processes in the development of Al
Praetego Inc Receives NIH Phase 2 STTR Funding to Advance Novel Amadorin Drug Candidates for Diabetic Peripheral Neuropathy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development Praetego Inc Receives NIH Phase 2 STTR Funding to Advance Novel Amadorin Drug Candidates for Diabetic Peripheral Neuropathy September 30, 2020 | 2 min read Twitter LinkedIn Facebook Email Print Praetego Inc (https://www.praetego.com/), a preclinical stage pharmaceutical company commit … iving with diabetes, is pleased to announce the approval of a 3 year $2.1M STTR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. DURHAM, N.C. , Sept. 30, 2020 /PRNewswire/ -- Praetego Inc ( https://www.praetego.com/ ), a preclinical stage pharmaceutical company committed to improving health outcomes for patients living with diabetes, is pleased to announce the approval of a 3 year $2.1M S … iving with diabetes, is pleased to announce the approval of a 3 year $2.1M STTR grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health. The award advances the Company's proprietary small molecules for the treatment of Diabetic Peripheral Neuropathy (DPN). This Phase 2 grant follows the successfully completed Phase 1 award from the NIDDK that identified potent drug candidates in the class of "Amadorins," whi … ntific Officer, Dr. Raja G. Khalifah , who is the principal investigator on the grant. Says Praetego CEO Pepper Landson, "The Amadorins offer hope for more than symptom management. By protecting diabetic patients from damage to their peripheral nervous system, they could live longer, healthier lives. More than extending life span, the Amadorins m
Praetego Inc Awarded New NIH Funding to Investigate Novel Small Molecule Drug Candidates for Neurodegeneration and Alzheimer's Disease. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufact … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Bio NC Praetego Inc Awarded New NIH Funding to Investigate Novel Small Molecule Drug Candidates for Neurodegeneration and Alzheimer’s Disease. June 18, 2021 | 2 min read Twitter LinkedIn Facebook Email Print Praetego Inc (https://www.praetego.com/), a pharmaceutical company committed to improving health outcomes for pat … omes for patients living with diabetes, is pleased to announce a $0.46M funding award from the National Institutes of Health. Durham, N.C ,, June 18, 2021 /PRNewswire/ -- Praetego Inc ( https://www.praetego.com/ ) , a pharmaceutical company committed to improving health outcomes for patients living with diabetes, is pleased to announce a $0.46M funding award from the National Institutes of Health. The award is funded by the National Institute of Diabetes and Diges … Diseases (NIDDK) in conjunction with the National Institute of Aging (NIA). The award advances the Company's proprietary small molecules in inhibiting Advanced Glycation End-products (AGEs) where the primary focus is on limiting disease progression in Diabetic Peripheral Neuropathy (DPN). The award offers Praetego a promising opportunity to extend their preclinical investigation of the lead candidate, PTG-630, in preventing progression of neurodegeneration in Alzheimer's Dise … k will be done in non-diabetic animal models of Alzheimer's Disease. This award supplements a Phase 2 STTR grant for Praetego's lead candidates, known as Amadorins, which are unique inhibitors of AGEs. AGE accumulation is correlated with all chronic disease of aging, and specifically, diabetic microvascular disease and neurodegeneration in
Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Bio NC Praetego Awarded $0.3M by National Eye Institute to Advance Novel Oral Drug for Diabetic Retinopathy March 1, 2023 | 2 min read Twitter LinkedIn Facebook Email Print Praetego Inc. is pleased to announce a $0.3M STTR award from the National Eye Institute. DURHAM, N.C., March 1, 2023 /PRNewswire/ -- ( https://www.p … eurodegenerative diseases related to aging, is pleased to announce a $0.3M STTR award from the National Eye Institute. The Phase 1 award advances Praetego's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy. Praetego's proprietary small molecules ("Amadorins") are already demonstrating neuroprotection in the central and peripheral nervous systems in multiple models of neurodegenerative diseases associated with aging. It is now established that … ped as a novel oral candidate for DR, a desired alternative to injectables. The award allows Praetego to establish the merits of PTG-630 ahead of a clinical program. Praetego's NEI grant expands PTG-630 to a third indication and builds upon promising findings in both Alzheimer's disease and diabetic peripheral neuropathy. It complements active awards from the National Institute of Aging and the National Institute of Diabetes and Digestive and Kidney Diseases. This award initi … RIES Obesity ADA: Novo boasts deep pipeline, ‘breadth of assets’ after analysts award Lilly weight loss gold June 8, 2026 · 5 min read · Heather McKenzie Weight loss ADA: Kailera ‘back at work’ after record-breaking IPO with China data in hand June 8, 2026 · 4 min read · Annalee
035 Improving Your Leadership Skills as a Science-Based Entrepreneur with Praetego Co-Founder & CEO, Pepper Landson | Supportedly Skip to content Learn Online Training Explore Content Search By Topic Ask Questions & Answers Ask a Question Find Support Directory Find Your Local Chapter Find Your SBC Log In Sign Up Learn Online Training Explore Content Search By Topic Ask Questions & Answers Ask a Question Find Support Directory Find Your Local Chapter Find Your SBC Log In Sign Up Podcasts 035 Improving Your Leadership Skills as a Science-Based Entrepreneur with Praetego Co-Founder & … p Season 1 with Our Favorite Entrepreneurial Advice Listen → 039 NC IDEA: Grant Application Best Practices & Mistakes to Avoid with John Austin Listen → Browse All Podcasts Receive Insights You Won't Delete, From Our Hearts To Your Brains Footer Email Signup Form Email Address * We won't share your email, but we can't wait to share our newsletter with you. * I agree to Supportedly's terms & conditions and privacy policy .* reCAPTCHA If you are human, leav
NEI award supports Praetego's development of PTG-630 for diabetic retinopathy | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's … overage of the Ebola outbreak See today's BioWorld Science Home » NEI award supports Praetego's development of PTG-630 for diabetic retinopathy To read the full story, subscribe or sign in . Ocular NEI award supports Praetego's development of PTG-630 for diabetic retinopathy March 2, 2023 Praetego Inc. has been granted a US$300,000 phase I Small Business Technology Transfer Research (STTR) award by the National Eye Institute (NEI) to advance the company's lead candi … proof of concept in diabetic retinopathy. BioWorld Science Collaboration Ocular Grant Popular Stories Today's news in brief BioWorld BioWorld briefs for June 9, 2026. New York University identifies new analogues of mannose-6-phosphate BioWorld Science New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,... ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins BioWorld If the
Praetego Inc. - Page 1 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T A … s the formation of advanced glycation end-products (AGEs). Read More Ocular NEI award supports Praetego's development of PTG-630 for diabetic retinopathy March 2, 2023 Praetego Inc. has been granted a US$300,000 phase I Small Business Technology Transfer Research (STTR) award by the National Eye Institute (NEI) to advance the company's lead candidate, PTG-630, into preclinical proof of concept in diabetic retinopathy. Read More Neurology/Psychiatric NIA award supports Praeteg … een awarded a US$2.5 million phase II Small Business Technology Transfer (STTR) award from the National Institute on Aging (NIA) to its advance lead candidate, PTG-630, for Alzheimer's disease. Read More Popular Stories Today's news in brief BioWorld BioWorld briefs for June 9, 2026. New York University identifies new analogues of mannose-6-phosphate BioWorld Science New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for
Praetego Inc - BIO International Convention | BIO Skip to main content --> Policy Get Involved Join BIOAction View Advocacy Toolkit Patient Advocacy Human Health Cost and Value of Biopharmaceuticals Antimicrobial Resistance Vaccines & Biodefense Drug Development & Review International Global Markets & Trade Multilateral Organizations Intellectual Property Science & Regulatory All Policy Patient Advocacy Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access. Member Membership Opt